Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
TBE Meningococcal Disease Influenza Smallpox
 
Prophylaxis

  MVA (Modified Vaccinia Ankara)

Together with Acambis, Baxter is developing a third generation smallpox vaccine based on the strain Modified Vaccinia Ankara (MVA). MVA is an attenuated form of the current generation of smallpox vaccines and, as such, is expected to allow the safe inoculation of “at risk” individuals with weakened immune systems, who could otherwise not be vaccinated against smallpox.

 » Printversion

 
 
  » find


 

Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
» read more

Baxter receives preparedness contract from Austrian Ministry of Health for Pandemic Influenza Vaccine
» read more

Baxter Announces Safety and Immunogenicity Results from Phase I/II Clinical Trial of Cell-Based Candidate H5N1 Pandemic Vaccine
» read more

 
Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,